Overview

To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors

Status:
Not yet recruiting
Trial end date:
2026-01-06
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, multicenter, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the experimental drug(SYHX2001) in previously treated patients with advanced or metastatic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.